DDInter554 DDInter899
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Digoxin {u} (Compound) resembles {v} (Compound) Deslanoside
Digoxin {u} (Compound) resembles {v} (Compound) Acetyldigitoxin
Digoxin {u} (Compound) binds {v} (Gene) ATP1A3
Digoxin {u} (Compound) upregulates {v} (Gene) RRN3
Digoxin {u} (Compound) palliates {v} (Disease) dilated cardiomyopathy
Digoxin {u} (Compound) is included by {v} (Pharmacologic Class) Cardiac Glycosides
Digoxin {u} (Compound) downregulates {v} (Gene) C17orf62
Digoxin {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticlopidine
Digoxin (Compound) resembles Deslanoside (Compound)
Digoxin (Compound) resembles Acetyldigitoxin (Compound)
Digoxin (Compound) binds ATP1A3 (Gene)
Digoxin (Compound) upregulates RRN3 (Gene)
Digoxin (Compound) palliates dilated cardiomyopathy (Disease)
Digoxin (Compound) is included by Cardiac Glycosides (Pharmacologic Class)
Digoxin (Compound) downregulates C17orf62 (Gene)
Digoxin (Compound) causes Thrombocytopenia (Side Effect)
Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Digoxin may cause a minor interaction that can limit clinical effects when taken with Ticlopidine